{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:55:10Z","timestamp":1776678910916,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009664","name":"Sociedad Espa\u00f1ola de Cardiolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004336","name":"Ministerio de Agricultura, Alimentaci\u00f3n y Medio Ambiente","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) is among the most prevalent arrhythmias. Its onset after an acute coronary syndrome (ACS) is especially notable given the high coronary disease burden. Mineral metabolism, particularly fibroblast growth factor 23 (FGF23), has been linked to cardiovascular outcomes. This study examines whether FGF23, related markers and other variables can predict AF occurrence after an ACS, considering age differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from the BACS &amp; BAMI study, including 1189 patients from five Madrid hospitals. Baseline clinical characteristics and laboratory results were recorded. Patients were monitored annually through clinical appointments. Univariate and multivariate Cox analyses were conducted separately for patients aged\u2009\u2264\u200965 and\u2009&gt;\u200965\u00a0years, based on CHA2DS2-VA thromboembolic score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a follow-up of 5.44 (3.03\u20137.46) years, 5.5% of patients developed AF. In those\u2009\u2264\u200965\u00a0years, FGF23 was an independent predictor of the development of AF (HR 1.37 [1.04, 1.79] per 100-unit rise;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). Among patients\u2009&gt;\u200965\u00a0years, a history of stroke was associated with a heightened risk (HR 2.75 [1.03, 7.34];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044), while beta-blocker therapy appeared to be protective (HR 0.42 [0.23, 0.78];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007). Previous AF consistently forecasted recurrence across both groups (HR 11.3 [2.92, 43.6];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002 and HR 6.41 [3.13, 13.1];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FGF23 seems to be an independent and positive predictor of AF after an ACS in patients\u2009\u2264\u200965\u00a0years, whereas in older individuals, beta\u2010blocker therapy emerges as a potential protective measure. These insights may enhance current risk models with age-specific adjustments and encourage more tailored clinical strategies in post-ACS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02898-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:23:50Z","timestamp":1776669830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting atrial fibrillation after an acute coronary syndrome: insights from the BACS &amp; BAMI study"],"prefix":"10.1007","author":[{"given":"Jaime Francisco","family":"Larre-Guerra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Castrillo-Capilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Garbayo-Bugeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kallmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Nieves","family":"Tar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Crist\u00f3bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Huelmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Guti\u00e9rrez-Landaluce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio Esteban","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junior","family":"Senra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Luisa","family":"Gonz\u00e1lez Casaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"L\u00f3pez-Besc\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mah\u00edllo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Rubio-Campal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1373-0999","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tu\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"2","key":"2898_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1747493019897870","volume":"16","author":"G Lippi","year":"2021","unstructured":"Lippi G, Sanchis-Gomar F, Cervellin G (2021) Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 16(2):217\u2013221","journal-title":"Int J Stroke"},{"issue":"6","key":"2898_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ehjqcco\/qcaa061","volume":"7","author":"H Dai","year":"2021","unstructured":"Dai H, Zhang Q, Much AA et al (2021) Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes 7(6):574\u201382","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2898_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4482","volume":"354","author":"A Odutayo","year":"2016","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopwell S, Altman DG, Emdin CA (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 354:i4482","journal-title":"BMJ"},{"issue":"3","key":"2898_CR4","first-page":"113","volume":"9","author":"AM Al-Kaisey","year":"2020","unstructured":"Al-Kaisey AM, Parameswaran R, Kalman JM (2020) Atrial fibrillation structural substrates: aetiology, identification and implications. Arrhythm Electrophysiol Rev 9(3):113\u2013120","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"19","key":"2898_CR5","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.110.990192","volume":"123","author":"P Jabre","year":"2011","unstructured":"Jabre P, Jouven X, Adnet F et al (2011) Atrial fibrillation and death after myocardial infarction: a community study. Circulation 123(19):2094\u20132100","journal-title":"Circulation"},{"issue":"5","key":"2898_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00774-015-0706-y","volume":"34","author":"E Gonz\u00e1lez-Parra","year":"2016","unstructured":"Gonz\u00e1lez-Parra E, Ace\u00f1a \u00c1, Lorenzo \u00d3 et al (2016) Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate. J Bone Miner Metab 34(5):587\u2013598","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2898_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/ehf2.14568","volume":"11","author":"A Kallmeyer","year":"2024","unstructured":"Kallmeyer A, Pello A, C\u00e1novas E et al (2024) Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome. ESC Heart Fail 11(1):240\u2013250","journal-title":"ESC Heart Fail"},{"issue":"6","key":"2898_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","volume":"3","author":"BA Bergmark","year":"2018","unstructured":"Bergmark BA, Udell JA, Morrow DA (2018Jun 1) Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial. JAMA Cardiol 3(6):473\u2013480","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2898_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/EJE-21-0891","volume":"187","author":"J Ishigami","year":"2022","unstructured":"Ishigami J, Yasuyuki H, Karger AM et al (2022) <article-title update=\"added\">18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC study. Eur J Endocrinol 187(1):39\u201347","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2898_CR10","first-page":"326","volume":"1","author":"S Fumagalli","year":"2015","unstructured":"Fumagalli S, Said SAM, Laroche C et al (2015) Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: the EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). J Am Coll Cardiol EP 1(4):326\u2013334","journal-title":"J Am Coll Cardiol EP"},{"issue":"11","key":"2898_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258770","volume":"16","author":"IS Kim","year":"2021","unstructured":"Kim IS, Choi YJ, Choi EY et al (2021) Comparison of risk profiles for new-onset atrial fibrillation between patients aged <60 and \u226560 years. PLoS ONE 16(11):e0258770","journal-title":"PLoS ONE"},{"issue":"3","key":"2898_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.amjcard.2013.10.012","volume":"113","author":"J Tu\u00f1\u00f3n","year":"2014","unstructured":"Tu\u00f1\u00f3n J, Blanco-Colio L, Crist\u00f3bal C et al (2014) Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol 113(3):434\u201340","journal-title":"Am J Cardiol"},{"issue":"9","key":"2898_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","volume":"30","author":"J Schmitt","year":"2009","unstructured":"Schmitt J, Duray G, Gersh BJ, Hohnloser SH (2009) Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30(9):1038\u20131045","journal-title":"Eur Heart J"},{"key":"2898_CR14","unstructured":"Ben Halima M, Yaakoubi W, Boudiche S et al (2022) New-onset atrial fibrillation after acute coronary syndrome: prevalence and predictive factors. Tunis Med 100(2):114\u201321"},{"issue":"14","key":"2898_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/2047487317715769","volume":"24","author":"V Ruddox","year":"2017","unstructured":"Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvarsen T, Otterstad JE (2017) Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol 24(14):1555\u20131566","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2898_CR16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/heartjnl-2015-308678","volume":"102","author":"G Batra","year":"2016","unstructured":"Batra G, Svennblad B, Held C et al (2016) All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart 102(12):926\u2013933","journal-title":"Heart"},{"issue":"2","key":"2898_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jjcc.2014.11.001","volume":"66","author":"H Gonz\u00e1lez-Pacheco","year":"2015","unstructured":"Gonz\u00e1lez-Pacheco H, M\u00e1rquez MF, Arias-Mendoza A et al (2015) Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. J Cardiol 66(2):148\u2013154","journal-title":"J Cardiol"},{"key":"2898_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132017","volume":"407","author":"JK Petersen","year":"2024","unstructured":"Petersen JK, Butt JH, Yafasova A et al (2024) Prognosis and antithrombotic practice patterns in patients with recurrent and transient atrial fibrillation following acute coronary syndrome: a nationwide study. Int J Cardiol 407:132017","journal-title":"Int J Cardiol"},{"key":"2898_CR19","doi-asserted-by":"crossref","unstructured":"Romanov A, Martinek M, P\u00fcrerfellner et al (2018) Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. Europace 20(2):263\u2013270","DOI":"10.1093\/europace\/euw344"},{"issue":"22","key":"2898_CR20","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1097\/CM9.0000000000002906","volume":"136","author":"Z Hu","year":"2023","unstructured":"Hu Z, Ding L, Yao Y (2023) Atrial fibrillation: mechanism and clinical management. Chin Med J (Engl) 136(22):2668\u20132676","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"2898_CR21","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21(9):1427\u20131435","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"2898_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026365","volume":"11","author":"L Li","year":"2022","unstructured":"Li L, Gan H (2022) Intact fibroblast growth factor 23 regulates chronic kidney disease-induced myocardial fibrosis by activating the sonic hedgehog signaling pathway. J Am Heart Assoc 11(18):e026365","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2898_CR23","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393\u20134408","journal-title":"J Clin Invest"},{"key":"2898_CR24","first-page":"2918","volume":"18","author":"M Liu","year":"2014","unstructured":"Liu M, Li XC, Lu L et al (2014) Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18:2918\u20132926","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2898_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM et al (2010) The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152:640\u2013648","journal-title":"Ann Intern Med"},{"issue":"4","key":"2898_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231905","volume":"15","author":"K Kuga","year":"2020","unstructured":"Kuga K, Kusakari Y, Uesugi K et al (2020) Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-\u03b21. PLoS ONE 15(4):e0231905","journal-title":"PLoS ONE"},{"issue":"4","key":"2898_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095402","volume":"9","author":"J Tu\u00f1\u00f3n","year":"2014","unstructured":"Tu\u00f1\u00f3n J, Crist\u00f3bal C, Tar\u00edn N et al (2014) Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One 9(4):e95402","journal-title":"PLoS One"},{"issue":"11","key":"2898_CR28","doi-asserted-by":"publisher","first-page":"19502","DOI":"10.1002\/jcp.28548","volume":"234","author":"Q Dong","year":"2019","unstructured":"Dong Q, Li S, Wang W et al (2019) FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways. J Cell Physiol 234(11):19502\u201319510","journal-title":"J Cell Physiol"},{"issue":"5","key":"2898_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jamacardio.2016.1445","volume":"1","author":"R Mehta","year":"2016","unstructured":"Mehta R, Cai X, Lee J et al (2016) Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol 1(5):548\u2013556","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2898_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.113.005499","volume":"130","author":"JS Mathew","year":"2014","unstructured":"Mathew JS, Sachs MC, Katz R et al (2014) Fibroblast growth factor-23 and incident atrial fibrillation: the multi-ethnic study of atherosclerosis (MESA) and the cardiovascular health study (CHS). Circulation 130(4):298\u2013307","journal-title":"Circulation"},{"issue":"13","key":"2898_CR31","first-page":"1003","volume":"98","author":"QB Dong","year":"2018","unstructured":"Dong QB, Tang YH, Wang WX et al (2018) Relationship between FGF23\/FGFR4 expression in atrial tissue and atrial fibrosis in patients with atrial fibrillation. Zhonghua Yi Xue Za Zhi 98(13):1003\u20131007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2898_CR32","doi-asserted-by":"publisher","first-page":"16743","DOI":"10.1038\/s41598-023-42331-7","volume":"13","author":"W Chua","year":"2023","unstructured":"Chua W, Cardoso VR, Guasch E et al (2023) An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions. Sci Rep 13:16743","journal-title":"Sci Rep"},{"key":"2898_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.899667","volume":"9","author":"Z Tan","year":"2022","unstructured":"Tan Z, Song T, Huang S et al (2022) Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: a systematic review and meta-analysis. Fron Cardiovasc Med 9:899667","journal-title":"Fron Cardiovasc Med"},{"issue":"1","key":"2898_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/anec.12004","volume":"18","author":"MF Khan","year":"2013","unstructured":"Khan MF, Wendel CS, Movahed MR (2013) Prevention of post-coronary artery bypass grafting (CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol 18(1):58\u201368","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2898_CR35","doi-asserted-by":"crossref","unstructured":"Poldermans D, Schouten O, Bax J et al (2009) Reducing cardiac risk in non-cardiac surgery: evidence from the DECREASE studies. Eur Heart J Supplements 11(A):9\u201314","DOI":"10.1093\/eurheartj\/sup004"},{"key":"2898_CR36","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","volume":"371","author":"POISE Study Group","year":"2008","unstructured":"POISE Study Group (2008) Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 371:1839\u20131847","journal-title":"Lancet"},{"issue":"2","key":"2898_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-0040-1708472","volume":"69","author":"SH Kim","year":"2021","unstructured":"Kim SH, Jang MJ, Hwang HY (2021) Perioperative beta-blocker for atrial fibrillation after cardiac surgery: a meta-analysis. Thorac Cardiovasc Surg 69(2):133\u2013140","journal-title":"Thorac Cardiovasc Surg"},{"issue":"1","key":"2898_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12916-020-01564-3","volume":"18","author":"OJ Ziff","year":"2020","unstructured":"Ziff OJ, Samra M, Howard JP et al (2020) Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 18(1):103","journal-title":"BMC Med"},{"issue":"7","key":"2898_CR39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.amjmed.2018.01.032","volume":"131","author":"A Oesterle","year":"2018","unstructured":"Oesterle A, Weber B, Tung R et al (2018) Preventing postoperative atrial fibrillation after noncardiac surgery: a meta-analysis. Am J Med 131(7):795-804.e5","journal-title":"Am J Med"},{"key":"2898_CR40","unstructured":"Van Gelder IC, Rienstra M, Bunting KV et al (2024) 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Hear J 45(36):3314\u2013414"},{"key":"2898_CR41","doi-asserted-by":"publisher","first-page":"17731","DOI":"10.1038\/srep17731","volume":"5","author":"TT Lin","year":"2016","unstructured":"Lin TT, Chiang JY, Liao MT et al (2016) Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. Sci Rep 5:17731","journal-title":"Sci Rep"},{"issue":"1","key":"2898_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijcard.2004.03.079","volume":"102","author":"AR Erbay","year":"2005","unstructured":"Erbay AR, Turhan H, Yasar AS et al (2005) Effects of long-term beta-blocker therapy on P-wave duration and dispersion in patients with rheumatic mitral stenosis. Int J Cardiol 102(1):33\u20137","journal-title":"Int J Cardiol"},{"issue":"4","key":"2898_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","volume":"28","author":"IA Nasr","year":"2007","unstructured":"Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P (2007) Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 28(4):457\u2013462","journal-title":"Eur Heart J"},{"issue":"5","key":"2898_CR44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Lehto M, Gerdts E (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45(5):712\u20139","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2898_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","volume":"152","author":"BA Schaer","year":"2010","unstructured":"Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR (2010) Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 152(2):78\u201384","journal-title":"Ann Intern Med"},{"issue":"3","key":"2898_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1590\/S1807-59322010000300005","volume":"65","author":"AE Pesaro","year":"2010","unstructured":"Pesaro AE, de Matos Soeiro A, Serrano CV, Rocha Giraldez R, Teixeira Ladeira R, Nicolau JC (2010) Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. Clinics (Sao Paulo) 65(3):265\u201370","journal-title":"Clinics (Sao Paulo)"},{"issue":"10","key":"2898_CR47","first-page":"1633","volume":"36","author":"CA Jackevicius","year":"2020","unstructured":"Jackevicius CA, Krumholz HM, Ross JS et al (2020) Clinical outcomes with beta-blocker use in patients with recent history of myocardial infarction. Can J Cardiol 36(10):1633\u20131640","journal-title":"Can J Cardiol"},{"issue":"38","key":"2898_CR48","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rosello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 44(38):3720\u20133826","journal-title":"Eur Heart J"},{"issue":"15","key":"2898_CR49","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","volume":"390","author":"T Yndigegn","year":"2024","unstructured":"Yndigegn T, Lindahl B, Mars K et al (2024) Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 390(15):1372\u201381","journal-title":"N Engl J Med"},{"key":"2898_CR50","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","volume":"391","author":"J Silvain","year":"2024","unstructured":"Silvain J, Cayla G, Ferrari E et al (2024) Beta-blocker interruption or continuation after myocardial infarction. N Eng J Med 391:1277\u20131286","journal-title":"N Eng J Med"},{"key":"2898_CR51","doi-asserted-by":"crossref","unstructured":"Ibanez B, Latini R, Rossello X, Dominguez-Rodriguez A, Fern\u00e1ndez-Vazquez F, Pelizzoni V et al (2025) Beta-blockersafter myocardial infarction without reduced ejection fraction. N Engl J Med 393:1889\u20131900","DOI":"10.1056\/NEJMoa2504735"},{"key":"2898_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505985","author":"J Munkhaugen","year":"2025","unstructured":"Munkhaugen J, Kristensen AMD, Halvorsen S, Holmager T, Olsen MH, Bakken A (2025) Beta-blockers after myocardial infarction in patients without heart failure. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2505985","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02898-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02898-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:03:44Z","timestamp":1776675824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02898-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":52,"alternative-id":["2898"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02898-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors do not declare any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}